IMR Press / FBE / Volume 7 / Issue 1 / DOI: 10.2741/E719

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Neuroprotective agents and modulation of temporal lobe epilepsy
Show Less
1 Department of Neurology and Neurosurgery, Universidade Federal de Sao Paulo-UNIFESP, Rua Pedro de Toledo, 669 - 2º andar, CEP 04039-032, Sao Paulo, SP, Brazil
2 Inserm U-666, Strasbourg, France

*Author to whom correspondence should be addressed.

Academic Editor: Antoni Camins

Front. Biosci. (Elite Ed) 2015, 7(1), 90–106; https://doi.org/10.2741/E719
Published: 1 January 2015
(This article belongs to the Special Issue Current advances in epilepsy and neurodegeneration)
Abstract

Temporal Lobe Epilepsy (TLE) is a chronic condition characterized by epileptic seizures originating mainly in temporal lobe areas. Epileptogenesis is a process in which a central nervous system injury can lead surviving neuronal populations to generate abnormal, synchronous and recurrent epileptiform discharges producing focal or generalized seizures. Hipocampal sclerosis, a massive cell death in the hippocampal formation and in the other regions of temporal lobe, is considered as hallmark of TLE. Despite the numerous antiepileptic drugs (AEDs) commercially available, about 30-40% of patients remain with seizures refractory to pharmacological treatment. In addition, there is no drug with significant efficacy to modify the epileptogenesis process. In this review we present some data regarding the neuroprotective effect of some adenosinergic agents, erythropoietin and carisbamate regarding the disease- and epileptogenesis-modifying effect.

Keywords
Temporal Lobe Epilepsy
Neuroprotection
Erytropoietin
Adenosine
Carisbamate
Review
Share
Back to top